more

Abaxis,Inc. (ABAX)

(Real Time Quote from BATS)

$83.00 USD

-0.09 (-0.11%)

Updated Jul 31, 2018 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.15%
2	Buy	17.88%
3	Hold	9.47%
4	Sell	5.14%
5	Strong Sell	2.57%
S&P	500	11.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Industry: NA

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Steer Clear of AmerisourceBergen Now (Revised)

by Zacks Equity Research Published on August 24,2018

AmerisourceBergen (ABC) continues to witness headwinds due to slowdown in hepatitis C revenues and conversion of branded drugs to the lower price generics.

HRC vs. ABAX: Which Stock Is the Better Value Option?

by Zacks Equity Research Published on July 25,2018

HRC vs. ABAX: Which Stock Is the Better Value Option?

Is Abaxis (ABAX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research Published on July 19,2018

Is (ABAX) Outperforming Other Medical Stocks This Year?

ABAXNegative Net Change

Is Abaxis (ABAX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research Published on July 19,2018

Is (ABAX) Outperforming Other Medical Stocks This Year?

ABAXNegative Net Change

Abaxis (ABAX) and Zoetis Merger Deal Crosses HRS Hurdle

by Zacks Equity Research Published on July 10,2018

With the adoption of Abaxis' (ABAX) point-of-care diagnostic instruments post acquisition, the combined entity's veterinary diagnostics category should grow faster than the animal health industry.

Zoetis (ZTS) Tides Over HSR Hurdle for Abaxis Acquisition

by Zacks Equity Research Published on July 09,2018

Zoetis' (ZTS) waiting period under the HSR Act ends. It is related to its proposed merger with Abaxis for a purchase consideration of roughly $2 billion in aggregate.

Top Ranked Momentum Stocks to Buy for July 9th

by Zacks Equity Research Published on July 09,2018

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 9th:

Here's Why You Should Add Abaxis (ABAX) to Your Portfolio

by Zacks Equity Research Published on June 29,2018

We are upbeat about Abaxis' (ABAX) solid consumable and instrument sales growth along with strength in the medical and veterinary market segments.

Cardiovascular Systems (CSII) in Focus: Stock Moves 7.7% Higher

by Zacks Equity Research Published on June 28,2018

Cardiovascular Systems (CSII) was a big mover last session, as the company saw its shares rise nearly 8% on the day.

Abaxis (ABAX) to be Acquired by Zoetis, Shares All-Time High

by Zacks Equity Research Published on May 17,2018

Post takeover of Abaxis' (ABAX) point-of-care diagnostic instruments, Zoetis expects the consolidated company's veterinary diagnostics category to speed up growth over the animal health industry.

Company News For May 17, 2018

by Zacks Equity Research Published on May 17,2018

Companies In The News are: FOXA,IQV,ABAX,ZTS,TEVA,BRK.B

Zoetis (ZTS) Inks Deal to Acquire Abaxis for $2 Billion

by Zacks Equity Research Published on May 17,2018

Zoetis (ZTS) inks a definitive deal to acquire Caifornia-based Abaxis, for $83 per share in cash or a total of $2 billion.

Abaxis (ABAX) Beats Earnings and Revenue Estimates in Q4

by Zacks Equity Research Published on April 27,2018

Abaxis (ABAX) Q4 earnings gain on strength in Medical and Veterinary segments.

Zacks.com highlights: Abaxis, Haynes International and Vectrus

by Zacks Equity Research Published on April 27,2018

Zacks.com highlights: Abaxis, Haynes International and Vectrus

Integra LifeSciences (IART) Tops on Q1 Earnings, '18 View Up

by Zacks Equity Research Published on April 26,2018

Integra LifeSciences' (IART) revenue growth was primarily driven by high organic revenues, successful progress with Codman integration and progress with the channel expansion strategy.

3 of the Best Stocks to Buy for Solid Earnings Acceleration

by Tirthankar Chakraborty Published on April 26,2018

If the rate of a company's quarter-over-quarter earnings growth increases within a stipulated frame of time, it can be referred to as earnings acceleration.